MyJournals Home  

RSS FeedsTreatment Choices for Front-line Metastatic Clear Cell Renal Cancer (European Urology)

 
 

29 january 2020 04:02:41

 
Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer (European Urology)
 


In this issue of European Urology, a study by Escudier et al [1] is published. This study builds on the previous publications investigating ipilimumab and nivolumab (IN) in metastatic renal cancer, including 30-month follow-up data [2,3]. The more recent publications show that IN maintains its overall survival (OS) advantage over sunitinib (OS hazard ratio [HR] 0.66 [95% confidence interval {CI} 0.45-0.80]), and there is a significant population that benefits from long-term remission. Finally, clinical benefit is broadly limited to patients with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- and poor-risk disease.


 
233 viewsCategory: Urology
 
Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas`s Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9 (European Urology)
Efficacy of vibegron, a novel ?3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study (BJU International)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten